Brexanolone produces ‘meaningful reductions’ in postpartum depression

October 4, 2018

Most women who received an injection of brexanolone — a positive allosteric modulator of -aminobutyric-acid type A receptors — for postpartum depression had significant and clinically meaningful reductions of the condition at 60 hours vs. placebo, according to findings recently published in The Lancet.

READ FULL ARTICLE ON HELIO.COM


Quick Links

What are you looking for? or call our Health Specialists at 1-844-HMH-Well